scholarly journals Diabetes mellitus is very common in drug resistant hypertension against angiotensin II receptor blocker and ACE inhibitor

2005 ◽  
Vol 18 (5) ◽  
pp. A57-A57
Author(s):  
K EGUCHI ◽  
K KARIO ◽  
J ISHIKAWA ◽  
S HOSHIDE ◽  
M MORINARI ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Angiotensin Ii ◽  
Resistant Hypertension ◽  
Ace Inhibitor ◽  
Receptor Blocker ◽  
Angiotensin Ii Receptor Blocker ◽  
Drug Resistant ◽  
Angiotensin Ii Receptor

Combination ACE Inhibitors and Angiotensin II Receptor Blockers for Hypertension

2003 ◽  
Vol 37 (6) ◽  
pp. 886-889 ◽  
Author(s):  
Patrick M Finnegan ◽  
Brenda L Gleason
Keyword(s):  
Blood Pressure ◽  
Angiotensin Ii ◽  
Combination Therapy ◽  
Ace Inhibitors ◽  
Ace Inhibitor ◽  
Renin Angiotensin System ◽  
Reduce Blood Pressure ◽  
Receptor Blocker ◽  
Angiotensin Ii Receptor Blocker ◽  
Angiotensin Ii Receptor

OBJECTIVE: To review data concerning combined angiotensin-converting enzyme (ACE) inhibitor and angiotensin II receptor blocker (ARB) therapy for hypertension. DATA SOURCES: MEDLINE (1966–April 2003), IPA (1970–April 2003), and EMBASE (1974–April 2003) with search terms of ACE inhibitor, angiotensin receptor blocker, essential hypertension, and combination therapy. DATA SYNTHESIS: ACE inhibitors provide incomplete blockade of the renin–angiotensin system, sometimes leading to loss of blood pressure control. Addition of ARBs may in theory further reduce blood pressure. Studies of combined ACE inhibitor and ARB therapy for managing hypertension were evaluated. CONCLUSIONS: While studies have shown statistically significant blood pressure reductions with ACE/ARB combination therapy, clinical significance is lacking. Further trials are needed before routine use of the combination can be recommended.

Sign in / Sign up

Export Citation Format

Share Document